BTAI INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline NEW YORK, July 22, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of persons and entities that purchased or acquired securities...

BIOXCEL THERAPEUTICS, INC. INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of persons and entities that purchased or acquired securities...

BTAI Shareholder News: Johnson Fistel Encourages BioXcel Therapeutics Shareholders with Losses to Contact the Firm Regarding Investigation SAN DIEGO, June 29, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether BioXcel Therapeutics (NASDAQ: BTAI), any of its...

BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...

BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive...